Circulating Tumor Cells (CTC) are cancer cells that have invaded blood vessels or the lymphatic system from the primary tumor. As the tumor grows, some cells detach from the primary tumor and spread through the bloodstream or lymphatic system, acting as "seeds" for metastasis. These "seeds" are known as circulating tumor cells (CTC), and are essentially cancer cells traveling throughout the body.
Avatar Medicine involves creating a "stand-in" for patients by collecting samples or data, enabling testing of various treatments. Using just 20cc of blood, an ex vivo cancer avatar can be created, sparing patients from trying multiple drugs. This marks a shift from a "one-size-fits-all" approach to cancer treatment to personalized cancer drug matching, achieving precision medicine.
Through blood samples, cancer patients can create personalized tumor avatars for ex vivo drug testing (including chemotherapy, hormone therapy, and targeted therapy). This approach directly evaluates drug efficacy, ensuring a personalized treatment plan while minimizing ineffective medication.
Avatar Medicine involves creating a "stand-in" for patients by collecting samples or data, enabling testing of various treatments. Using just 20cc of blood, an ex vivo cancer avatar can be created, sparing patients from trying multiple drugs. This marks a shift from a "one-size-fits-all" approach to cancer treatment to personalized cancer drug matching, achieving precision medicine.
Through blood samples, cancer patients can create personalized tumor avatars for ex vivo drug testing (including chemotherapy, hormone therapy, and targeted therapy). This approach directly evaluates drug efficacy, ensuring a personalized treatment plan while minimizing ineffective medication.
The library of testable drugs is up to 100 combinations, spanning chemotherapy drugs, hormonal drugs and targeted drugs.
Fully customized drug list, selected by the physician to test the drug, can be combined with genetic testing to achieve further personalized precision medicine.
Only requires blood specimens which is easy to collect and suitable for patients who have difficulty obtaining tissue samples or elderly patients.
Compared to tissue specimens, blood samples show more heterogeneity and are more representative than local tissue samples when tumors have developed distant metastases.
Genetic testing analyzes a patient’s genetic information to identify mutated genes and match them with potential existing drugs, providing gene-level data . EVA Select tests drug sensitivity on patient cancer cells at the cellular level, reducing the risk of ineffective medication by providing sensitivity data as a result from direct cellular testing.
Genetic testing analyzes a patient’s genetic information to identify mutated genes and match them with potential existing drugs, providing gene-level data . EVA Select tests drug sensitivity on patient cancer cells at the cellular level, reducing the risk of ineffective medication by providing sensitivity data as a result from direct cellular testing.
"Put The Patient First" is our company's highest guiding principle.
Our goal is to reduce the pain and risks experienced by cancer patients during treatment and to enhance precision in medication usage during the golden window of treatment.
All solid tumors, such as lung cancer, breast cancer, colorectal cancer, prostate cancer, ovarian cancer, liver cancer, stomach cancer, pancreatic cancer, kidney cancer, bladder cancer, skin cancer, sarcoma, brain cancer, and more, including various rare types of cancer, amount to over 120 types of solid tumor cancers!
Genes exist within cells and carry the genetic information that indirectly influences cellular behavior. Normal cells contain tens of thousands of genes, and among those, over 500 genes are currently known to have the potential to transform a normal cell into a cancer cell. Targeting these genes may be possible to match them with existing drugs and further speculate on their potential to inhibit a patient’s cancer cells.
EVA Select, however, does not focus on discussing gene regulatory mechanisms. Instead, it directly evaluates drug sensitivity by assessing the tolerance level of the patient’s cancer cells to various drugs. This approach avoids indirect speculation and directly tests the effectiveness of drugs, thereby reducing the risk of patients receiving ineffective treatments.
© 2024 All Right Reserved